UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1961) 1961
Book Chapter (71) 71
Publication (3) 3
Dissertation (2) 2
Magazine Article (2) 2
Book / eBook (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1533) 1533
life sciences & biomedicine (1488) 1488
humans (1371) 1371
female (1354) 1354
breast cancer (1062) 1062
breast neoplasms - drug therapy (942) 942
oncology (862) 862
aromatase inhibitors (690) 690
aromatase inhibitors - therapeutic use (575) 575
aromatase (486) 486
tamoxifen (457) 457
middle aged (449) 449
cancer (429) 429
aged (394) 394
animals (388) 388
aromatase inhibitor (364) 364
breast neoplasms - pathology (359) 359
antineoplastic agents, hormonal - therapeutic use (351) 351
care and treatment (339) 339
aromatase inhibitors - adverse effects (308) 308
postmenopause (308) 308
tamoxifen - therapeutic use (291) 291
medicine & public health (283) 283
chemotherapy, adjuvant (262) 262
endocrine therapy (259) 259
postmenopausal women (250) 250
estrogen (242) 242
treatment outcome (237) 237
adult (234) 234
aromatase - metabolism (225) 225
male (223) 223
health aspects (218) 218
research (217) 217
nitriles - therapeutic use (208) 208
triazoles - therapeutic use (208) 208
letrozole (204) 204
toxicology (203) 203
pharmacology & pharmacy (202) 202
antineoplastic agents - therapeutic use (196) 196
chemotherapy (196) 196
estrogens (195) 195
aromatase inhibitors - administration & dosage (193) 193
analysis (188) 188
anastrozole (188) 188
aged, 80 and over (181) 181
breast neoplasms - metabolism (177) 177
drug therapy (172) 172
clinical trials (154) 154
antineoplastic agents, hormonal - adverse effects (152) 152
aromatase - genetics (149) 149
hematology, oncology and palliative medicine (148) 148
receptors, estrogen - metabolism (142) 142
metastasis (141) 141
cancer therapies (140) 140
risk factors (138) 138
exemestane (135) 135
clinical trials as topic (134) 134
antineoplastic combined chemotherapy protocols - therapeutic use (131) 131
disease-free survival (129) 129
aromatase inhibitors - pharmacology (127) 127
menopause (127) 127
breast neoplasms - mortality (122) 122
randomized controlled trials as topic (120) 120
neoplasm staging (118) 118
obstetrics & gynecology (117) 117
triazoles - adverse effects (117) 117
womens health (117) 117
neoplasms, hormone-dependent - drug therapy (116) 116
adjuvant treatment (115) 115
nitriles - adverse effects (115) 115
patients (113) 113
rats (113) 113
quality of life (111) 111
androstadienes - therapeutic use (109) 109
breast neoplasms - genetics (109) 109
hormones (108) 108
endocrinology & metabolism (107) 107
nitriles - administration & dosage (105) 105
triazoles - administration & dosage (105) 105
antineoplastic agents, hormonal - administration & dosage (103) 103
tamoxifen - administration & dosage (103) 103
enzymes (102) 102
gene expression (100) 100
toxicity (99) 99
dose-response relationship, drug (98) 98
abridged index medicus (94) 94
tamoxifen - adverse effects (92) 92
breast neoplasms - surgery (91) 91
estradiol (91) 91
prognosis (91) 91
review (90) 90
post-menopause (88) 88
biochemistry & molecular biology (86) 86
breast neoplasms - prevention & control (86) 86
internal medicine (85) 85
time factors (83) 83
oncology, experimental (82) 82
tumors (82) 82
antineoplastic agents - adverse effects (81) 81
prevention (81) 81
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2027) 2027
Japanese (15) 15
German (5) 5
French (4) 4
Portuguese (4) 4
Spanish (4) 4
Chinese (2) 2
Polish (2) 2
Italian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 09/2011, Volume 103, Issue 17, pp. 1299 - 1309
Journal Article
British journal of dermatology (1951), ISSN 0007-0963, 09/2017, Volume 177, Issue 3, pp. 882 - 882
Journal Article
Clinical cancer research, ISSN 1557-3265, 01/2017, Volume 23, Issue 1, pp. 26 - 34
Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110 alpha, has shown synergistic antitumor activity with endocrine therapy againstER... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thiazoles - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Biomarkers, Tumor | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Neoplasm Metastasis | DNA Mutational Analysis | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | In Situ Hybridization, Fluorescence | Treatment Outcome | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Line, Tumor | Aged | Mutation | Neoplasm Staging | Letrozole | Therapy | Toxicity | p53 Protein | Exanthema | Clinical trials | Metastasis | K-Ras protein | Metastases | Gene sequencing | Anticancer properties | Hyperglycemia | Catalysis | Fibroblast growth factor receptor 1 | Deoxyribonucleic acid--DNA | Diarrhea | Endocrine therapy | Fatigue | Nausea | Breast cancer | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | Experimental design | Antitumor activity | Tumors | DNA sequencing | Cancer | Index Medicus
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 10/2019, Volume 179, Issue 2, pp. 275 - 285
Background Endocrine therapy with aromatase inhibitors (AIs) is the cornerstone of adjuvant systemic treatment for postmenopausal patients with hormone receptor-positive breast cancer... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Care and treatment | Analysis | Adjuvant treatment | Postmenopausal women | Breast cancer | Societies | Hormones | Associations, institutions, etc | Health aspects | Cancer | Index Medicus
Journal Article
Breast cancer research and treatment, ISSN 0167-6806, 07/2017, Volume 164, Issue 2, pp. 411 - 419
Aromatase inhibitors (AI), which decrease circulating estradiol concentrations in post-menopausal women, are associated with toxicities that limit adherence... 
Patient outcome assessment | Crossover | Arthralgia | Aromatase inhibitors | Quality of life | Life Sciences & Biomedicine | Oncology | Science & Technology | Care and treatment | Patient outcomes | Analysis | Menopause | Phenols | Postmenopausal women | Estradiol | Index Medicus
Journal Article
Critical reviews in oncology/hematology, ISSN 1040-8428, 12/2020, Volume 156, pp. 103114 - 103114
[Display omitted] Extended endocrine therapy (EET) with aromatase inhibitors (AIs) therapy can further reduce the risk of recurrence in breast cancer patients... 
Endocrine therapy | Side effects | Breast cancer | Extend | Aromatase inhibitors | Index Medicus
Journal Article
Journal Article
The breast journal, ISSN 1524-4741, 09/2019, Volume 26, Issue 2, pp. 255 - 257
.... Specific toxicity of the CDK 4/6 inhibitor ribociclib was retained. Once transaminase levels normalized, the patient initiated another CDK4/6 inhibitor, palbociclib, using an escalating dose without reappearance of hepatic injury... 
elevated transaminase | luminal breast cancer | rechallenge | CDK 4/6 inhibitor | hepatic toxicity | Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Cyclin-dependent kinase | Inhibitors | Toxicity | Transaminase | Transaminases | Liver | Aromatase | Breast cancer | Kinases | Cyclin-dependent kinase 4 | Metastases
Journal Article